Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Apollomics Inc

APLM ✗ NOT COMPLIANT ☆ Track — members

Nasdaq · Financials · Investment Holding Companies ·

USA Micro Cap Analyst: N/A

Last Close

$22.40

▲ +29.63%

Market Cap $51.39M · Vol 12.72K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$51.39M

Micro Cap

Div Yield

N/A

EPS Growth

N/A

YoY

RSI (14)

68.04

Momentum

Beta

1.56

vs Market

52W High

$42.12

46.82% below

52W Low

$3.69

507.05% above

Volume

12.72K

Avg 5.08K

P/B

N/A

Price-to-book

ROE

N/A

Return on equity

Free Float

52.90%

Public shares

Shariah Compliance8 STANDARDS

✗ Apollomics Inc (APLM) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does APLM pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+28.07%

+42.68%

+57.86%

+13.19%

YTD

+15.70%

+286.21%

-95.78%

N/A

Financials & Valuation

TTM · Annual

Total Revenue	$8.50M
Net Income	$-10,939,000.00
Revenue Growth (YoY)	N/A
Gross Margin	100.00%
Operating Margin	-111.59%
Net Profit Margin	-128.69%
ROE	N/A
ROA · ROIC	-110.40% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	3.18
P/B	N/A
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	2.20M

Technical Indicators

50-Day SMA	$17.84
200-Day SMA	$17.31
RSI (14)	68.04
Beta	1.56
52-Week High	$42.12
52-Week Low	$3.69

Volume Today	12.72K
Avg Daily Volume (30D)	5.08K
Relative Volume	2.51x
Volatility (10D)	135.83
Volatility (30D)	160.30
Free Float	52.90%

Analyst Consensus

N/A

Current Price $22.40

Mean Target N/A

52W Low$3.69 52W High$42.12

Current

Target

$3.69 $42.12

Current Analyst target

· 0 analysts

Identifiers

ExchangeNasdaq

FIGIBBG00DQ8QDR9

ISINKYG0411D1236

CountryUnited States of America

Sub-IndustryInvestment Holding Companies (NEC)

Earnings DateN/A

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2POINTZERO.AD Two Point Zero Group PJSC -0.50% LATO B.ST Investment AB Latour +0.08% REM.J Remgro Ltd +0.17% NCCI.KW National Consumer Holding Company KSCP -1.99% MUBARRAD.KW Mubarrad Holding Co KSCP -2.17%

Company Profile

Apollomics Inc. is a clinical-stage biopharmaceutical company focusing on discovering and developing oncology therapies to address unmet medical needs, especially for difficult-to-treat and treatment-resistant cancers. The product candidates in its pipeline are categorized into two groups based on their mechanisms of action, each of which contains product candidates at different stages of development: tumor inhibitors and immuno-oncology drugs. Its tumor inhibitor product candidates consist of three small-molecule inhibitors against different uncontrolled growth signaling pathways in cancer cells: vebreltinib, APL-102 and APL-122. Its three immuno-oncology product candidates consist of APL-501, APL-502 and APL-80. Vebreltinib is a potent, oral active selective c-Met inhibitor. APL-102 is an oral active, small molecule Multiple Tyrosine Kinase Inhibitor. APL-122 is a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathways. APL-501 is an anti-PD-1 antibody product candidate.